Acarix Receives Strategic Investment from Puhua Jingxin

Acarix, a Swedish/Danish commercial stage medical device company, received a double-digit SEK million strategic investment from Chinese Puhua Jingxin Guzhou Health Management Partnership.

The company intends to use the funds to ramp up both production of the CE-marked CADScor®System and sales organization.

Established in 2009 as a spin-out company from Coloplast A/S and led by Søren Rysholt Christiansen, CEO, Acarix specializes in non-invasive, non-radiation acoustic detection of Coronary Artery Disease (CAD). The CADScor®System combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a handheld device to provide a patient specific CAD-score in less than 10 minutes.
The system is CE Marked (by TÜV in 2015) and due for commercial launch in 2017. The collaboration with Puhua Jingxin will enhance Acarix’s ongoing market entry strategy which has an initial focus on Germany, UK, Sweden and Denmark.

The company is also backed by Seed Capital and Sunstone Life Science Ventures.




Join the discussion